Dr. Reddy's Laboratories, Global Response Aid, and Appili Therapeutics announce the filing of an application for Reeqonus (favipiravir) tablets for the treatment of COVID-19 under Health Canada’s Interim Order

Dr. Reddy’s Laboratories

22 December 2020 - Dr. Reddy’s Laboratories, Appili Therapeutics and Global Response Aid today announced that Dr. Reddy’s Canada has filed an application on behalf of the consortium for Reeqonus (favipiravir) tablets for the acute treatment of mild to moderate COVID-19 adult patients under Health Canada’s Interim Order Respecting the Importation, Sale and Advertising of Drugs for Use in Relation to COVID-19. 

Reeqonus is also known as Avigan (favipiravir) tablets developed by Fujifilm.

Read Dr Reddy's Laboratories press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , Canada , Dossier , COVID-19